1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd

860.00
INR
-16.95
(-1.93%)
4.22BMarket Cap
Jenburkt Pharmaceuticals Ltd
BSE:JENBURPH
(Bombay Stock Exchange)

Recent

price

860.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
122.42
128.66
149.15
163.95
183.28
201.29
222.2
249.87
267.24
259.06
237.22
269.6
298.18
320.92
342.98
381.38
- -
Revenue per Share
12.94
12.89
13.37
16.15
20.75
23.18
29.05
37.5
43.14
32.4
35.96
48.58
53.9
58.86
72.65
78.71
- -
Basic EPS, GAAP
7.26
5.77
4.62
22.52
16.98
11.37
20.6
34.28
23.06
22.8
39.9
13.55
32.74
12.62
18.56
29.01
- -
Free Cash Flow per Basic Share
3.5
3.5
4.2
5.1
6.3
7.2
-0.4
14.41
3.18
18.7
- -
10.2
12.05
14.32
15.36
17.99
- -
Dividend per Share
31.31
40.23
48.72
58.73
71.92
87.58
117.09
133.48
168.79
174.32
214.55
255.77
277.32
328.42
389.23
446.47
- -
Book Value per Share
31.08
40.06
48.59
58.69
71.87
87.23
116.81
133.22
168.44
172.49
213.5
255.1
276.9
327.54
388.71
445.92
- -
Tangible Book Value per Share
5
5
5
5
5
5
5
5
5
5
5
5
5
4
4
4
4
Basic Weighted Avg Shares
569
598
693
762
852
936
1,033
1,147
1,226
1,189
1,089
1,237
1,361
1,416
1,514
1,683
- -
Sales/Revenue/Turnover
16.19
13.8
12.44
13.07
14.78
15.46
17.39
19.62
19.26
14.67
16.36
20.49
20.65
21.73
24.89
24.14
- -
Operating Margin (%)
10
12
15
16
27
20
18
15
14
23
20
19
23
23
27
31
- -
Depreciation Expense
60
60
62
75
96
108
135
172
198
149
165
223
246
260
321
347
- -
Net Income, GAAP
33.82
29.64
29.56
27.33
32.71
35.95
34.04
31.88
25.67
29.65
23.75
25.35
25.13
26.15
27.02
25.33
- -
Effective Tax Rate (%)
10.57
10.02
8.96
9.85
11.32
11.52
13.08
15.01
16.14
12.51
15.16
18.02
18.07
18.34
21.18
20.64
- -
Profit Margin (%)
122
129
169
169
250
309
456
529
671
697
620
546
653
933
377
719
- -
Working Capital
1
1
- -
- -
- -
2
2
2
- -
14
9
5
- -
- -
15
18
- -
LT Debt
146
187
227
273
334
407
544
613
775
800
985
1,174
1,224
1,449
1,718
1,970
- -
Total Equity
37.92
31.07
25.24
25.65
24.49
21.49
22.23
24.82
23.95
14.4
14.36
16.83
17.04
16.91
17.3
15.41
- -
Return on Invested Capital (%)
39.9
31.77
25.77
27.42
28.47
25.51
25.68
28.52
27.4
17.89
17.83
19.82
19.91
19.35
20.17
18.66
- -
Return on Capital (%)
48.33
36.05
30.06
30.05
31.77
29.07
28.39
29.75
28.54
18.89
18.49
20.66
20.53
19.43
20.25
18.84
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
6
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
18
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
4,810
4,217
4,897

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
951
- -
Cash, Cash Equivalents & STI
- -
473
- -
Accounts Receivable, Net
- -
244
- -
Inventories
- -
136
- -
Total Current Liabilities
- -
231
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
6
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.42%
15.03%
14.71%
Free Cash Flow
30.15%
23.01%
56.3%
Net Income, GAAP
13.67%
16.56%
8.34%
Sales/Revenue/Turnover
6.26%
9.16%
11.2%
Total Cash Common Dividend
- -
- -
17.09%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
325
412
369
410
1,514
2026
355
- -
430
446
1,683
2027
355
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
16.8
21.75
14.75
19.34
72.65
2026
17.66
- -
13.44
24.58
78.71
2027
13.34
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
15.36
2026
- -
- -
- -
- -
17.99
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations and healthcare products in India and internationally across 13 countries. Founded in 1985 and headquartered in Mumbai, India, the company offers a broad portfolio of prescription and over-the-counter drugs spanning therapeutic areas including anti-fungals, anti-ulcerants and antacids, aphrodisiacs, anti-malarials, anthelmintics, anti-diabetics, pain management, analgesics and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain treatments, anti-arthritics, anti-infectives, cough and cold remedies, dermatological products, and consumer healthcare items; key brands include Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega, Nervijen P, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zixa, and Zydol Suspension. The company operates a WHO-GMP approved manufacturing plant in Sihor, Gujarat, supported by an R&D unit approved by the Ministry of Science and Technology, Government of India, and serves government institutions, hospitals, pharmacies, and over 100,000 doctors through more than 1,000 stockists and 400,000 pharmacies globally. In recent developments, Jenburkt Pharmaceuticals reports consistent revenue and profit growth, with net profit rising 5.83% to Rs 10.16 crore and sales up 10.53% to Rs 45.56 crore in the quarter ended September 2025; the company also launched a new over-the-counter division, Jenburkt Wellness, in fiscal year 2021-22 to expand into physical wellness products, increased its final dividend to Rs 18 per share in 2025, and maintains steady institutional holdings while adopting technologies like SAP S4 HANA for operational efficiency.